HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
USFDA completes cGMP audit at Cohance Lifesciences’ Andhra Pradesh facility
Sep-12-2025

The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences’ API manufacturing facility (API Unit-1) located at Jaggaiahpet, Andhra Pradesh. The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations. 

The company remains committed to maintaining the highest standards of quality and regulatory compliance in all its operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. 


  RELATED NEWS >>